CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS

The aim of the study was to conduct a pharmacoeconomic evaluation of the atezolizumab, vemurofenib and cobimetinib (ATZ+VM+COB) combination and the nivolumab and ipilimumab (NIVO+IPI) combination for the treatment of BRAF-confirmed metastatic melanoma in adult patients.Materials and methods. With th...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova
Formatua:	Artigo
Hizkuntza:	Russo
Argitaratua:	Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2022-07-01
Saila:	Фармация и фармакология (Пятигорск)
Gaiak:	metastatic melanoma braf mutations melanoma treatment “cost-effectiveness” analysis “budget impact” analysis atezolizumab vemurafenib cobimetinib
Sarrera elektronikoa:	https://www.pharmpharm.ru/jour/article/view/1120
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!